Hemochromatosis - Pipeline Insight, 2021
SKU ID :DEL-17687650 | Published Date: 15-Mar-2021 | No. of pages: 60Description
TOC
Introduction
Executive Summary
Hemochromatosis: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Hemochromatosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Hemochromatosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Hemochromatosis Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
PTG-300: Protagonist Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
Matriptase-2 inhibitor: Disc Medicine
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Hemochromatosis Key Companies
Hemochromatosis Key Products
Hemochromatosis- Unmet Needs
Hemochromatosis- Market Drivers and Barriers
Hemochromatosis- Future Perspectives and Conclusion
Hemochromatosis Analyst Views
Hemochromatosis Key Companies
Appendix
Tables & Figures
Table 1 Total Products for Hemochromatosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Companies
• Protagonist Therapeutics
• Disc Medicine
• Silence Therapeutics
• La Jolla Pharmaceutical Company
- PRICE
-
$1500$4500